Rate of discontinuation and reasons for discontinuation of intravesical onabotulinum toxin A treatment in patients with symptomatic Overactive Bladder (OAB) - G. Scrimgeour; K. Aleksejeva; R. Axell; H. Yasmin; M. Nadeem; M.H. Pakzad; R. Hamid; J.L. Ockrim; T.J. Greenwell (European Urology Open Science, 2020)